NO975585L - C-4' modifiserte adenosin-kinase inhibitorer - Google Patents

C-4' modifiserte adenosin-kinase inhibitorer

Info

Publication number
NO975585L
NO975585L NO975585A NO975585A NO975585L NO 975585 L NO975585 L NO 975585L NO 975585 A NO975585 A NO 975585A NO 975585 A NO975585 A NO 975585A NO 975585 L NO975585 L NO 975585L
Authority
NO
Norway
Prior art keywords
kinase inhibitors
adenosine kinase
modified adenosine
adenosine
substituents
Prior art date
Application number
NO975585A
Other languages
English (en)
Other versions
NO975585D0 (no
Inventor
Serge H Boyer
Mark D Erion
Bheemarao G Ugarkar
Original Assignee
Gensia Sicor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gensia Sicor filed Critical Gensia Sicor
Publication of NO975585D0 publication Critical patent/NO975585D0/no
Publication of NO975585L publication Critical patent/NO975585L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det er beskrevet adenosinkinase inhibitorer og nukleosidanaloger, C-4' modifiserte pyrroio [2,3-d]pyrimidin og pyrasolo [3,4-d]pyrimidin nukleosid analoger som har aktivitet som adenosinkinanse inhibitorer. Det er beskrevet nukleosidanaloger av denne typen som har O substituenter eller 2 substituenter ved C-4'-stillingen av furanose (sukker)-enheten. Det er videre beskrevet fremstilling og anvendelse av disse adenosinkinase inhibitorene ved behandlingen av kardiovaskulære og cerebrovaskulære sykdommer, inflammasjon og andre sykdommer som kan reguleres ved økning av den lokale konsentrasjonen av adenosin.
NO975585A 1995-06-07 1997-12-03 C-4' modifiserte adenosin-kinase inhibitorer NO975585L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/486,161 US5674998A (en) 1989-09-15 1995-06-07 C-4' modified adenosine kinase inhibitors
PCT/US1996/010404 WO1996040705A1 (en) 1995-06-07 1996-06-07 C-4' modified adenosine kinase inhibitors

Publications (2)

Publication Number Publication Date
NO975585D0 NO975585D0 (no) 1997-12-03
NO975585L true NO975585L (no) 1998-02-05

Family

ID=23930844

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975585A NO975585L (no) 1995-06-07 1997-12-03 C-4' modifiserte adenosin-kinase inhibitorer

Country Status (24)

Country Link
US (1) US5674998A (no)
EP (1) EP0832091B1 (no)
JP (1) JPH11507387A (no)
KR (1) KR19990022740A (no)
CN (1) CN1190401A (no)
AP (1) AP9701165A0 (no)
AT (1) ATE257841T1 (no)
AU (1) AU6178396A (no)
BG (1) BG102163A (no)
BR (1) BR9609013A (no)
CA (1) CA2220642A1 (no)
CZ (1) CZ392797A3 (no)
DE (1) DE69631330T2 (no)
EA (1) EA199800009A1 (no)
HU (1) HUP9802193A3 (no)
IL (1) IL122335A0 (no)
IS (1) IS4621A (no)
MX (1) MX9709859A (no)
NO (1) NO975585L (no)
OA (1) OA10639A (no)
PL (1) PL323904A1 (no)
SK (1) SK166097A3 (no)
TR (1) TR199701539T1 (no)
WO (1) WO1996040705A1 (no)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2109796T3 (es) * 1994-05-03 1998-01-16 Ciba Geigy Ag Derivados de pirrolopirimidilo con efecto antiproliferante.
PL188959B1 (pl) * 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
US6051578A (en) * 1996-02-12 2000-04-18 Pfizer Inc. Pyrazolopyrimidines for treatment of CNS disorders
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
PL354094A1 (en) * 1999-08-27 2003-12-29 Icn Pharmaceuticals, Inc.Icn Pharmaceuticals, Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
US6831069B2 (en) 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
KR20020088406A (ko) 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
WO2001043731A2 (en) * 1999-12-16 2001-06-21 Alcon, Inc. Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage
BR0104461A (pt) * 2000-02-10 2002-08-06 Mitsui Chemicals Inc Processo seletivo para produzir um anÈmero a partir de um derivado de sacarìdeo 1-fosforilado e processo para produzir um nucleosìdeo
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US7414036B2 (en) * 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
AU2002951247A0 (en) * 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
BRPI0400869B8 (pt) * 2004-03-02 2021-05-25 Univ Estadual Campinas Unicamp novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
WO2006084281A1 (en) 2005-02-04 2006-08-10 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
EP1915053A2 (en) * 2005-08-12 2008-04-30 Merck & Co., Inc. Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
HRP20120786T1 (hr) 2006-02-02 2012-11-30 Millennium Pharmaceuticals, Inc. Inhibitori aktivirajuä†eg enzima e1
KR20150038395A (ko) 2006-04-04 2015-04-08 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
EP2430026A1 (en) 2009-05-14 2012-03-21 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
KR102072041B1 (ko) 2011-12-22 2020-01-31 앨리오스 바이오파마 인크. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EA025186B1 (ru) 2012-06-29 2016-11-30 Пфайзер Инк. НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2
CA2886240A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
AU2014302715B2 (en) 2013-06-26 2018-12-06 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN105829333A (zh) 2013-10-11 2016-08-03 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016066582A1 (en) 2014-10-28 2016-05-06 Bci Pharma Nucleoside kinase inhibitors
AU2016301188A1 (en) 2015-08-06 2018-02-15 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
US11111264B2 (en) 2017-09-21 2021-09-07 Chimerix, Inc. Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof
PL4010330T3 (pl) 2019-08-08 2026-03-16 Hirundo Biosciences Pochodne chinoliny jako inhibitory kinazy białkowej
WO2021133915A1 (en) * 2019-12-23 2021-07-01 Sanford Burnham Prebys Medical Discovery Institute Ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) modulators and uses thereof
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
AU2022256476B2 (en) 2021-04-16 2025-06-05 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
KR102639275B1 (ko) * 2021-06-08 2024-02-21 퓨쳐메디신 주식회사 다중 표적 인산화효소 저해 활성을 갖는 뉴클레오사이드 유도체 및 이를 포함하는 암의 예방 및 치료용 약학적 조성물
CA3228162A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4455420A (en) * 1983-01-13 1984-06-19 Hoffmann-La Roche Inc. 4-Amino-7-(5-deoxy-beta-D-ribofuranosyl)-5-iodo-7H-pyrrolo[2,3-d] pyrimidine
DE3712735A1 (de) * 1987-04-15 1988-11-10 Boehringer Mannheim Gmbh Neue pyrazolo(3,4-d)pyrimidine, verfahren zu ihrer herstellung und verwendung als arzneimittel
WO1992012718A1 (en) * 1991-01-23 1992-08-06 Gensia, Inc. Adenosine kinase inhibitors
FI933303L (fi) * 1991-01-23 1993-08-31 Gensia Inc Adenosinkinasinhibitorer
WO1994018215A1 (en) * 1993-02-03 1994-08-18 Gensia, Inc. Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds

Also Published As

Publication number Publication date
IS4621A (is) 1997-11-26
OA10639A (en) 2002-09-17
CA2220642A1 (en) 1996-12-19
DE69631330T2 (de) 2004-10-28
AU6178396A (en) 1996-12-30
BG102163A (en) 1998-10-30
EP0832091B1 (en) 2004-01-14
PL323904A1 (en) 1998-04-27
SK166097A3 (en) 1999-06-11
KR19990022740A (ko) 1999-03-25
NO975585D0 (no) 1997-12-03
MX9709859A (es) 1998-08-30
CN1190401A (zh) 1998-08-12
US5674998A (en) 1997-10-07
HUP9802193A2 (hu) 1999-05-28
AP9701165A0 (en) 1998-01-31
ATE257841T1 (de) 2004-01-15
TR199701539T1 (xx) 1998-04-21
JPH11507387A (ja) 1999-06-29
HUP9802193A3 (en) 1999-10-28
WO1996040705A1 (en) 1996-12-19
BR9609013A (pt) 1999-12-14
DE69631330D1 (de) 2004-02-19
EP0832091A1 (en) 1998-04-01
CZ392797A3 (cs) 1999-04-14
IL122335A0 (en) 1998-04-05
EA199800009A1 (ru) 1998-06-25

Similar Documents

Publication Publication Date Title
TR199701539T1 (xx) C-4'Modifiye edilmi� adenosin kinaz inhibit�rleri.
ATE296309T1 (de) Wasserlösliche adenosin kinase inhibitoren
ATE282628T1 (de) Oral aktive adenosinkinase-inhibitoren
Nomura et al. Nucleosides and nucleotides. 185. Synthesis and biological activities of 4 ‘α-C-Branched-Chain sugar pyrimidine nucleosides
Hao et al. Factors determining the activity of 2', 3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro.
Carson et al. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase (s)
Balzarini et al. 2', 3'-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis.
Sanghvi et al. Antitumor and antiviral activity of synthetic. alpha.-and. beta.-ribonucleosides of certain substituted pyrimido [5, 4-d] pyrimidines: a new synthetic strategy for exocyclic aminonucleosides
Brink et al. Metabolism and distribution of 9-β-D-arabinofuranosyladenine in mouse tissues
Meier et al. cyclo Sal-Pronucleotides of 2 ‘-Fluoro-ara-and 2 ‘-Fluoro-ribo-2 ‘, 3 ‘-dideoxyadenosine as a Strategy to Bypass a Metabolic Blockade
EP0653439A3 (de) Stabilisierte Oligonucleotide und deren Verwendung.
NO912606D0 (no) Fremgangsmaate for fremstilling av 9-purinylfosfonsyrederivater.
Uberti et al. The effect of nucleosides and deoxycoformycin on adenosine and deoxyadenosine inhibition of human lymphocyte activation
SE9502474L (sv) Farmaceutiska kompositioner för förhindrande och behandling av cancerösa sjukdomar samt process för beredning av dessa
Piper et al. Biochemical basis for the differential sensitivity of human T-and B-lymphocyte lines to 5-fluorouracil
Ray Intracellular interactions between nucleos (t) ide inhibitors of HIV reverse transcriptase
Pisarev et al. Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication
NO932287L (no) 2'-deosky-2',2'-difluor(2,6,8-substituerte)purin-nukleosider med antiviralog anticanceraktivitet, og mellomprodukter
DK0720604T3 (da) Konformationelt låste nukleosidanaloger
FI91763C (fi) Menetelmä terapeuttisesti käyttökelpoisen 2',3'-dideoksi-3'-fluoripyrimidiini- tai -puriininukleosidin valmistamiseksi
BR0016162A (pt) Composições e métodos para l-nucleosìdeos, lnucleotìdeos e seus análogos
Leoutsakos et al. The effect of adenosine and its analogues on cyclic AMP changes and histamine secretion from rat peritoneal mast cells stimulated by various ligands
Kaufman et al. Comparison of specific antiviral agents in herpes simplex keratitis
Montgomery The design of chemotherapeutic agents
Törnevik et al. 2', 3'-Dideoxycytidine toxicity in cultured human CEM T lymphoblasts: effects of combination with 3'-azido-3'-deoxythymidine and thymidine.